Vontobel Holding
VRTX icon

Vontobel Holding’s Vertex Pharmaceuticals VRTX Stock Holding History

Vontobel Holding’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.5M Sell
81,525
-1,855
-2% -$822K 0.13% 157
2026
Q1 		$37.2M Sell
83,380
-21,907
-21% -$10.2M 0.13% 150
2025
Q4 		$47.7M Sell
105,287
-5,355
-5% -$2.31M 0.15% 119
2025
Q3 		$43.3M Buy
110,642
+38,844
+54% +$16.2M 0.13% 117
2025
Q2 		$32M Sell
71,798
-3,008
-4% -$1.39M 0.1% 150
2025
Q1 		$36.3M Sell
74,806
-114,143
-60% -$53.2M 0.13% 119
2024
Q4 		$76.1M Buy
188,949
+75,653
+67% +$35.1M 0.26% 64
2024
Q3 		$52.7M Sell
113,296
-45,534
-29% -$21.9M 0.17% 102
2024
Q2 		$74.4M Buy
158,830
+50,450
+47% +$21.9M 0.24% 65
2024
Q1 		$45.3M Buy
108,380
+46,946
+76% +$19.8M 0.36% 72
2023
Q4 		$25M Sell
61,434
-6,200
-9% -$2.29M 0.21% 121
2023
Q3 		$23.5M Sell
67,634
-363
-0.5% -$127K 0.22% 119
2023
Q2 		$23.9M Buy
67,997
+10,387
+18% +$3.5M 0.21% 122
2023
Q1 		$18.2M Sell
57,610
-5,089
-8% -$1.53M 0.17% 142
2022
Q4 		$17.9M Buy
62,699
+3,573
+6% +$1.09M 0.18% 137
2022
Q3 		$17.3M Sell
59,126
-13,662
-19% -$3.93M 0.2% 118
2022
Q2 		$20.4M Sell
72,788
-17,903
-20% -$4.79M 0.22% 112
2022
Q1 		$23.3M Sell
90,691
-26,006
-22% -$6.17M 0.2% 111
2021
Q4 		$26M Buy
116,697
+18,953
+19% +$3.69M 0.22% 106
2021
Q3 		$17.7M Buy
97,744
+19,318
+25% +$3.77M 0.16% 129
2021
Q2 		$15.4M Buy
78,426
+11,786
+18% +$2.47M 0.13% 137
2021
Q1 		$14.3M Buy
66,640
+8,572
+15% +$1.88M 0.11% 131
2020
Q4 		$12.4M Buy
+58,068
New +$13.3M 0.08% 155

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vontobel Holding's VRTX Position: Q2 2026 in Review

Vontobel Holding reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q2 2026, selling an estimated $822K and leaving 81,525 shares worth $40.5M. The position accounts for 0.13% of the portfolio, ranked #157.

Vontobel Holding first reported a position in VRTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $76.1M in Q4 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Vontobel Holding held 81,525 shares of Vertex Pharmaceuticals worth $40.5M as of Q2 2026.
  • Vontobel Holding sold 1,855 Vertex Pharmaceuticals shares in Q2 2026, an estimated $822K.
  • Vertex Pharmaceuticals made up 0.13% of Vontobel Holding's portfolio in Q2 2026, its #157 holding.
  • Vontobel Holding first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Vontobel Holding's Vertex Pharmaceuticals position peaked at $76.1M in Q4 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Vontobel Holding's 13F filing for Q2 2026, filed 3 Aug 2026.